Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells

Leukemia and Lymphoma

Volumn 42, Issue 3, 2001, Pages 417-427

  Sharp, J G ^a   Bishop, M R ^a   Copple, B ^a   Greiner, T C ^a   Iversen, P L ^a   Jackson, J D ^a   Joshi, S S ^a   Benner, E J ^a   Mann, S L ^a   Rao, A K ^a   Vose, J M ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cytotoxicity; Enhanced cytotoxicity; Idarubicin; Lymphoma cells; Oligonucleotide

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; IDARUBICIN; MESSENGER RNA; OLIGONUCLEOTIDE; PROTEIN P53; RIBONUCLEASE H;

ANIMAL CELL; APHERESIS; APOPTOSIS; ARTICLE; BONE MARROW PURGING; CELL DEATH; CELL GROWTH; COLONY FORMING CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG UPTAKE; GENE EXPRESSION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; INCUBATION TIME; LYMPHOMA; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TIME; WESTERN BLOTTING;

EID: 0034902588     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109064599     Document Type: Article

References (45)

1. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
2. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
3. Phase I trial of an antisense oligonucleotide OL(1) p53 in hematologic malignancies
4. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1) p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome
5. Antisense oligonucleotide OL(1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia
6. The challenge of p53 linking biochemistry, biology, and patient management
7. 2 arrest after DNA damage
8. IMVP-16. An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
9. The new genetic medicines
10. Antisense therapy for lymphomas
11. A p53-dependent mouse spindle checkpoint
12. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
13. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
14. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
15. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia
16. Nucleic acid therapeutics: State of the art and future prospects
17. Stem cell transplantation in acute leukemia
18. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma
19. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis
20. Mdm2 promotes the rapid degradation of p53
21. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
22. Oligonucleotides complementary to c-myb messenger RNA inhibit growth and induce apoptosis in human Burkitt lymphoma cells
23. Participation of p53 protein in the cellular response to DNA damage
24. ACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma
25. Immunomagnetic removal of B-lymphoma cells from human bone marrow: A procedure for clinical use
26. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
27. p53 status and the efficacy of cancer therapy in vivo
28. Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma
29. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines
30. p53: The ultimate tumor suppressor gene?
31. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
32. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53
33. Wild type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53
34. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas
35. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
36. Detection and relevance of minimal disease in lymphomas
37. Outcome of High-Dose Therapy and Autologous Transplantation in Non-Hodgkin's Lymphoma Based on the Presence of Tumor in the Marrow or Infused Hematopoietic Harvest
38. Induction of apoptosis by wild-type p53 in a human colon tumor derived cell line
39. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD of M-BACOD
40. Bone marrow purging. High-Dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells
41. Antisense oligonucleotides as therapeutics: Is the bullet really magical?
42. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood
43. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and Dexamethasone (DHAP)
44. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells